| Literature DB >> 7699217 |
M Woloschak1, K Post, J L Roberts.
Abstract
Antisense oligonucleotides have been investigated in recent years as potential new therapeutic agents because of their ability to shut off gene expression. Antisense DNA and RNA oligomers can bind specifically to mRNA preventing protein translation. We have studied the ability of an antisense POMC oligomer to reduce the expression of POMC in human ACTH-secreting pituitary adenoma cells cultured from 2 uncommon ACTH-secreting macroadenomas. In separate experiments, tumor tissue was enzymatically dispersed, cultured for 4 days, and treated with and without an antisense POMC oligonucleotide for 18 hours. In addition, cells from one tumor were treated with dexamethasone and cells from the other tumor were treated with an unrelated oligomer as controls. RNA was prepared from cultured cells and POMC mRNA was quantitated in a RNase protection assay using a human POMC RNA probe. ACTH in the media was quantitated by RIA. Tumor cells responded to 250 nmol/L dexamethasone with diminished POMC mRNA and ACTH levels 18 hours after treatment (decreased by 28% and 67% of control respectively). In both tumors, a POMC antisense oligomer at a concentration of 50 mumol/L lowered POMC mRNA levels and detectable ACTH levels in the media 18 hours after treatment, with mRNA levels decreased by 76% and 62% of control and ACTH levels decreased by 58% and 48% of control. Conversely, tumor cells treated with an unrelated oligomer at a 50 mumol/L concentration showed minimal effect on POMC mRNA and ACTH levels 18 hours after treatment (decreased by 2.3% and 1.5% of control respectively).(ABSTRACT TRUNCATED AT 250 WORDS)Entities:
Mesh:
Substances:
Year: 1994 PMID: 7699217 DOI: 10.1007/BF03347783
Source DB: PubMed Journal: J Endocrinol Invest ISSN: 0391-4097 Impact factor: 4.256